Key result
Non-selective NSAIDs and COX-2 inhibitors are linked to adverse cardiorenal and pro-thrombotic effects.
Why the study?
The cardiorenal harmful effects of some nsNSAIDs and COX-2 inhibitors are well described but the mechanisms and class-specificity remain unclear.
Do nsNSAIDs and COX-2 inhibitors increase the risk of adverse cardiorenal effects in patients with musculoskeletal conditions?
Do nsNSAIDs and COX-2 inhibitors increase the risk of adverse cardiorenal effects in patients with musculoskeletal conditions?
This review highlights the significant cardiorenal risks associated with both non-selective NSAIDs and COX-2 inhibitors, emphasizing the need for caution, especially in high-risk populations.
No takes yet. Share an insight, caveat, or question.
Urges vigilance with NSAID use in cardiovascular patients; leaves open precise risk estimates from randomized data.
Aneja et al. (2008) conducted a review in Musculoskeletal conditions. nsNSAIDs and COX-2 inhibitors was evaluated. Non-selective NSAIDs and COX-2 inhibitors are associated with adverse cardiorenal effects, including increased blood pressure, congestive heart failure, and pro-thrombotic effects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: